Artelo Biosciences (ARTL) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Artelo Biosciences (ARTLResearch Report) today and set a price target of $4.00. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.54.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 30.6% and a 36.9% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Achieve Life Sciences.

Currently, the analyst consensus on Artelo Biosciences is a Moderate Buy with an average price target of $3.50.

See today’s best-performing stocks on TipRanks >>

Artelo Biosciences’ market cap is currently $16.2M and has a P/E ratio of -1.30. The company has a Price to Book ratio of 1.76.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Read More on ARTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed